Please Wait
Applying Filters...
menu
    • menu
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Teneligliptin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 812Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 11Canalia

    02 15Tenelia

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Canalia

    Teneligliptin

    arrow
    BPI Europe
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    BPI Europe
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 137

    2019 Revenue in Millions : 112

    Growth (%) : 22

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Tenelia

    Teneligliptin

    arrow
    Bioequity Europe
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    Bioequity Europe
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 222

    2019 Revenue in Millions : 230

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Tenelia

    Teneligliptin

    arrow
    BPI Europe
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    BPI Europe
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 200

    2020 Revenue in Millions : 220

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Canalia

    Teneligliptin

    arrow
    BPI Europe
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    BPI Europe
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 139

    2020 Revenue in Millions : 136

    Growth (%) : 11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Canalia

    Teneligliptin

    arrow
    BPI Europe
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    BPI Europe
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 80

    2019 Revenue in Millions : 69

    Growth (%) : 16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Tenelia

    Teneligliptin

    arrow
    BPI Europe
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    BPI Europe
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 138

    2019 Revenue in Millions : 147

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Tenelia

    Teneligliptin

    arrow
    BPI Europe
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    BPI Europe
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 133

    2020 Revenue in Millions : 137

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Canalia

    Teneligliptin

    arrow
    IPEC-Americas
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    IPEC-Americas
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 84

    2020 Revenue in Millions : 79

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Canalia

    Teneligliptin

    arrow
    IPEC-Americas
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    IPEC-Americas
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 73

    2021 Revenue in Millions : 88

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Canalia

    Teneligliptin

    arrow
    BPI Europe
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    BPI Europe
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 125

    2021 Revenue in Millions : 139

    Growth (%) : -10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF